去年，艾伯维表现最佳的业务板块Immunology-SKYRIZI实现营收17.56B美元。United States的营收贡献最高，去年达到44.49B美元。最近一个季度，截至2026-06-30，艾伯维表现最佳的业务板块Immunology-SKYRIZI实现营收5.50B美元。United States的营收贡献最高，达到12.15B美元。

业务

营业收入

占比

年报

年报

单季报

Immunology-SKYRIZI

Immunology-RINVOQ

Immunology-HUMIRA

Neuroscience-Botox Therapeutic

Neuroscience-Vraylar

Hematologic Oncology-IMBRUVICA

Hematologic Oncology-VENCLEXTA

Aesthetics-Botox Cosmetic

Other Key Products-Creon

Other Key Products - Mavyret

Neuroscience-Ubrelvy

Aesthetics-Other Aesthetics

Neuroscience- Qulipta

Eye Care - Other Eye care

Collaboration revenue

Aesthetics-Juvederm collection

Other Key Products - Linzess/Constella

Hematologic Oncology- Elahere

Eye care - Ozurdex

Neuroscience - Vyalev

Eye Care - Lumigan/Ganfort

Neuroscience-Duodopa

Hematologic Oncology Epkinly

Neuroscience-Other Neuroscience

Eye Care - Alphagan/combigan

Hematologic oncology-other

Eye Care - Restasis

Hepatitis C Virus-MAVYRET

Other Key Products-Lupron

Other Key Products-Synthroid

Women's Health - Lo Loestrin

Women's Health - Other Women's Health

Women's Health - Orilissa/Oriahnn

Other Key Products-Synagis

Other Key Products-Duodopa

Other Key Products-Sevoflurane

Other Key Products-Kaletra

Other Key Products-AndroGel

Other Key Products-ORILISSA

Hepatitis C Virus-VIEKIRA

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Immunology-SKYRIZI

17.56B(29.50%)

11.72B(21.57%)

7.76B(15.14%)

5.17B(9.58%)

2.94B(5.49%)

1.59B(3.71%)

355.00M(1.08%)

Immunology-RINVOQ

8.30B(13.95%)

5.97B(10.99%)

3.97B(7.74%)

2.52B(4.68%)

1.65B(3.08%)

731.00M(1.70%)

47.00M(0.14%)

Immunology-HUMIRA

4.54B(7.63%)

8.99B(16.56%)

14.40B(28.09%)

21.24B(39.39%)

20.69B(38.66%)

19.83B(46.25%)

19.17B(58.52%)

Neuroscience-Botox Therapeutic

3.77B(6.33%)

3.28B(6.04%)

2.99B(5.83%)

2.72B(5.04%)

2.45B(4.58%)

1.39B(3.23%)

--(--)

Neuroscience-Vraylar

3.62B(6.08%)

3.27B(6.01%)

2.76B(5.38%)

2.04B(3.78%)

1.73B(3.23%)

951.00M(2.22%)

--(--)

Hematologic Oncology-IMBRUVICA

2.87B(4.82%)

3.35B(6.16%)

3.60B(7.01%)

4.57B(8.47%)

5.41B(10.10%)

5.31B(12.39%)

4.67B(14.27%)

Hematologic Oncology-VENCLEXTA

2.79B(4.69%)

2.58B(4.76%)

2.29B(4.46%)

2.01B(3.73%)

1.82B(3.40%)

1.34B(3.12%)

792.00M(2.42%)

Aesthetics-Botox Cosmetic

2.60B(4.37%)

2.72B(5.01%)

2.68B(5.23%)

2.62B(4.85%)

2.23B(4.17%)

1.11B(2.59%)

--(--)

Other Key Products-Creon

1.51B(2.54%)

1.38B(2.55%)

1.27B(2.47%)

1.28B(2.37%)

1.19B(2.23%)

1.11B(2.60%)

1.04B(3.18%)

Other Key Products - Mavyret

1.32B(2.21%)

1.31B(2.41%)

1.43B(2.79%)

1.54B(2.86%)

754.00M(1.41%)

785.00M(1.83%)

--(--)

Neuroscience-Ubrelvy

1.27B(2.13%)

1.01B(1.85%)

815.00M(1.59%)

680.00M(1.26%)

552.00M(1.03%)

125.00M(0.29%)

--(--)

Aesthetics-Other Aesthetics

1.26B(2.12%)

1.28B(2.35%)

1.23B(2.41%)

1.29B(2.39%)

1.47B(2.74%)

760.00M(1.77%)

--(--)

Neuroscience- Qulipta

1.04B(1.74%)

658.00M(1.21%)

408.00M(0.80%)

158.00M(0.29%)

--(--)

Eye Care - Other Eye care

1.01B(1.69%)

847.00M(1.56%)

803.00M(1.57%)

1.18B(2.18%)

1.17B(2.18%)

693.00M(1.62%)

--(--)

Collaboration revenue

1.00B(1.68%)

1.02B(1.87%)

--(--)

Aesthetics-Juvederm collection

993.00M(1.67%)

1.18B(2.17%)

1.38B(2.69%)

1.43B(2.65%)

1.53B(2.87%)

718.00M(1.67%)

--(--)

Other Key Products - Linzess/Constella

907.00M(1.52%)

954.00M(1.76%)

1.11B(2.16%)

1.03B(1.92%)

1.04B(1.94%)

667.00M(1.56%)

--(--)

Hematologic Oncology- Elahere

690.00M(1.16%)

479.00M(0.88%)

--(--)

Eye care - Ozurdex

493.00M(0.83%)

494.00M(0.91%)

472.00M(0.92%)

--(--)

Neuroscience - Vyalev

482.00M(0.81%)

--(--)

Eye Care - Lumigan/Ganfort

410.00M(0.69%)

429.00M(0.79%)

432.00M(0.84%)

514.00M(0.95%)

579.00M(1.08%)

378.00M(0.88%)

--(--)

Neuroscience-Duodopa

381.00M(0.64%)

447.00M(0.82%)

468.00M(0.91%)

458.00M(0.85%)

511.00M(0.95%)

494.00M(1.15%)

--(--)

Hematologic Oncology Epkinly

271.00M(0.46%)

146.00M(0.27%)

31.00M(0.06%)

--(--)

Neuroscience-Other Neuroscience

207.00M(0.35%)

338.00M(0.62%)

276.00M(0.54%)

475.00M(0.88%)

685.00M(1.28%)

539.00M(1.26%)

--(--)

Eye Care - Alphagan/combigan

197.00M(0.33%)

248.00M(0.46%)

272.00M(0.53%)

346.00M(0.64%)

529.00M(0.99%)

326.00M(0.76%)

--(--)

Hematologic oncology-other

33.00M(0.06%)

--(--)

Eye Care - Restasis

--(--)

224.00M(0.41%)

436.00M(0.85%)

666.00M(1.24%)

1.29B(2.41%)

787.00M(1.84%)

--(--)

Hepatitis C Virus-MAVYRET

--(--)

956.00M(1.79%)

1.04B(2.44%)

2.89B(8.83%)

Other Key Products-Lupron

--(--)

783.00M(1.46%)

752.00M(1.75%)

887.00M(2.71%)

Other Key Products-Synthroid

--(--)

767.00M(1.43%)

771.00M(1.80%)

786.00M(2.40%)

Women's Health - Lo Loestrin

--(--)

437.00M(0.82%)

356.00M(0.83%)

--(--)

Women's Health - Other Women's Health

--(--)

214.00M(0.40%)

192.00M(0.45%)

--(--)

Women's Health - Orilissa/Oriahnn

--(--)

145.00M(0.27%)

125.00M(0.29%)

--(--)

Other Key Products-Synagis

--(--)

718.00M(2.19%)

Other Key Products-Duodopa

--(--)

461.00M(1.41%)

Other Key Products-Sevoflurane

--(--)

348.00M(1.06%)

Other Key Products-Kaletra

--(--)

283.00M(0.86%)

Other Key Products-AndroGel

--(--)

172.00M(0.53%)

Other Key Products-ORILISSA

--(--)

93.00M(0.28%)

Hepatitis C Virus-VIEKIRA

--(--)

36.00M(0.11%)

地区

营业收入

占比

年报

年报

单季报

United States

International

All other countries

Germany

Japan

Canada

China

Collaboration revenue

France

United Kingdom

Spain

Italy

Brazil

Australia

The Netherlands

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

44.49B(63.60%)

40.78B(63.53%)

39.81B(64.51%)

42.98B(65.55%)

42.25B(65.89%)

33.81B(64.09%)

24.07B(57.14%)

International

13.04B(18.64%)

11.51B(17.92%)

11.47B(18.59%)

10.94B(16.69%)

11.28B(17.58%)

9.07B(17.20%)

8.69B(20.63%)

All other countries

2.63B(3.76%)

3.03B(4.72%)

3.04B(4.92%)

4.14B(6.31%)

2.67B(4.17%)

2.92B(5.54%)

3.99B(9.48%)

Germany

1.74B(2.48%)

1.47B(2.28%)

1.27B(2.05%)

1.34B(2.04%)

1.22B(1.91%)

1.05B(1.99%)

909.00M(2.16%)

Japan

1.27B(1.82%)

1.12B(1.75%)

1.01B(1.63%)

956.00M(1.46%)

1.09B(1.70%)

1.20B(2.27%)

1.21B(2.88%)

Canada

1.22B(1.75%)

1.09B(1.69%)

1.08B(1.74%)

1.16B(1.77%)

1.40B(2.18%)

1.16B(2.20%)

813.00M(1.93%)

China

1.01B(1.44%)

917.00M(1.43%)

950.00M(1.54%)

912.00M(1.39%)

857.00M(1.34%)

471.00M(0.89%)

--(--)

Collaboration revenue

1.00B(1.43%)

1.02B(1.58%)

--(--)

France

806.00M(1.15%)

776.00M(1.21%)

780.00M(1.26%)

787.00M(1.20%)

936.00M(1.46%)

797.00M(1.51%)

695.00M(1.65%)

United Kingdom

626.00M(0.89%)

522.00M(0.81%)

417.00M(0.68%)

462.00M(0.70%)

497.00M(0.78%)

509.00M(0.96%)

372.00M(0.88%)

Spain

609.00M(0.87%)

528.00M(0.82%)

501.00M(0.81%)

506.00M(0.77%)

519.00M(0.81%)

453.00M(0.86%)

472.00M(1.12%)

Italy

580.00M(0.83%)

511.00M(0.80%)

484.00M(0.78%)

444.00M(0.68%)

506.00M(0.79%)

379.00M(0.72%)

372.00M(0.88%)

Brazil

478.00M(0.68%)

464.00M(0.72%)

439.00M(0.71%)

430.00M(0.66%)

368.00M(0.57%)

406.00M(0.77%)

359.00M(0.85%)

Australia

459.00M(0.66%)

463.00M(0.72%)

472.00M(0.76%)

508.00M(0.77%)

533.00M(0.83%)

527.00M(1.00%)

--(--)

The Netherlands

--(--)

163.00M(0.39%)